Respirion has announced the successful completion of its Phase 1b study of RSP-1502, an inhaled antibiotic combination for the treatment of chronic lung infections in cystic fibrosis.
With safety confirmed in patients aged 12 and above, the program will now advance into a Phase 2a efficacy study across multiple clinical sites in Australia and the United States, evaluating its impact on infection burden and lung inflammation.
